Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roser Torra

Showing results (141-150 of 161) with videos related to

Pageof 17
Sort By:
BMJ Open|October 11, 2020
Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiativeDerralynn A Hughes, Patricio Aguiar, Patrick B Deegan, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 7, 2026
Incidence and prevalence of kidney replacement therapy in central and eastern europe -trends from the ERA registryMarjolein Bonthuis, Anneke Kramer, Sevcan A Bakkaloğlu, et al.
Clinical Kidney Journal|June 1, 2023
Autosomal dominant polycystic kidney disease in young adultsVíctor Martínez, Mónica Furlano, Laia Sans, et al.
European Journal of Human Genetics : EJHG|January 23, 2023
Correction: The 2019 and 2021 International workshops on Alport syndromeSergio Daga, Jie Ding, Constantinos Deltas, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 8, 2022
An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease InternationalRoman-Ulrich Müller, A Lianne Messchendorp, Henrik Birn, et al.
European Journal of Human Genetics : EJHG|March 9, 2022
The 2019 and 2021 International Workshops on Alport SyndromeSergio Daga, Jie Ding, Constantinos Deltas, et al.
Journal of the American Society of Nephrology : JASN|July 10, 2010
Genetic variation of DKK3 may modify renal disease severity in ADPKDMichelle Liu, Sally Shi, Sean Senthilnathan, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 21, 2022
Effects of Bardoxolone Methyl in Alport SyndromeBradley A Warady, Pablo E Pergola, Rajiv Agarwal, et al.
Kidney International|December 15, 2011
Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancyOliver Gross, Christoph Licht, Hans J Anders, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 23, 2025
Nephrectomy in autosomal dominant polycystic kidney disease: a consensus statement of the ERA Genes & Kidney Working GroupPaul Geertsema, Ron T Gansevoort, Mustafa Arici, et al.
Pageof 17

Showing results (141-150 of 161) with videos related to

Sort By:
Pageof 17
BMJ Open|October 11, 2020
Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiativeDerralynn A Hughes, Patricio Aguiar, Patrick B Deegan, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 7, 2026
Incidence and prevalence of kidney replacement therapy in central and eastern europe -trends from the ERA registryMarjolein Bonthuis, Anneke Kramer, Sevcan A Bakkaloğlu, et al.
Clinical Kidney Journal|June 1, 2023
Autosomal dominant polycystic kidney disease in young adultsVíctor Martínez, Mónica Furlano, Laia Sans, et al.
European Journal of Human Genetics : EJHG|January 23, 2023
Correction: The 2019 and 2021 International workshops on Alport syndromeSergio Daga, Jie Ding, Constantinos Deltas, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 8, 2022
An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease InternationalRoman-Ulrich Müller, A Lianne Messchendorp, Henrik Birn, et al.
European Journal of Human Genetics : EJHG|March 9, 2022
The 2019 and 2021 International Workshops on Alport SyndromeSergio Daga, Jie Ding, Constantinos Deltas, et al.
Journal of the American Society of Nephrology : JASN|July 10, 2010
Genetic variation of DKK3 may modify renal disease severity in ADPKDMichelle Liu, Sally Shi, Sean Senthilnathan, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 21, 2022
Effects of Bardoxolone Methyl in Alport SyndromeBradley A Warady, Pablo E Pergola, Rajiv Agarwal, et al.
Kidney International|December 15, 2011
Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancyOliver Gross, Christoph Licht, Hans J Anders, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 23, 2025
Nephrectomy in autosomal dominant polycystic kidney disease: a consensus statement of the ERA Genes & Kidney Working GroupPaul Geertsema, Ron T Gansevoort, Mustafa Arici, et al.
Pageof 17